Adults with Attention Deficit Hyperactivity Disorder (ADHD), especially teenagers and young adults, show important car driving impairments, including risky driving, accidents, fines and suspension of driver's license. We systematically reviewed the efficacy of stimulant and nonstimulant drugs on driving performance of ADHD patients. We searched several databases for randomized controlled trials (RCTs) published through March, 2013. Fifteen RCTs (the majority with crossover design) evaluated methylphenidate (MPH) immediate-release (MPH-IR), MPH osmotic-controlled oral system (MPH-OROS), MPH transdermal system (MTS), extended-release mixed amphetamine salts (MAS-XR); atomoxetine (ATX) and lisdexamfetamine (LDX). Methods varied widely; including simulators and/or cars and different courses and scenarios. Various outcomes of driving performance, including a 'composite' or 'overall' driving score were considered. In general, stimulants improved driving performance in ADHD patients (either in RCTs conducted in simulators and/or cars). MPH-OROS improved driving performance compared with MAS-XR, placebo, or no-drug conditions. Although MPH-OROS and MPH-IR produced similar improvements during the day, MPH-IR lost its efficacy in the evening. MAS-XR also improved driving performance, but worsened driving performance in the evening. MTS (one study) showed a positive effect, but drug compliance varied widely across patients. LDX had positive effect on driving (two studies with the same sample). Studies with ATX report conflicting results. Improvement was more consistent in teenagers and young adults. In general, treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving www.elsevier.com/locate/euroneuro http://dx
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a common psychiatric disorder that emerges during childhood and persists throughout the lifespan (Biederman and Faraone, 2005; affecting 5.3% of children and 4.4% of adults worldwide . ADHD is characterized by inattention, hyperactivity, and impulsivity, which results in several social and functional impairments (Barkley et al., 1996) . Adults with ADHD exhibit a variety of impairments in their daily academic, professional, economic, interpersonal, and affective lives (Barkley et al., 2002; Wilens et al., 2004) .
Driving involves multiple complex cognitive functions, including perception, motor coordination, and executive function, which are usually impaired in patients with ADHD (Barkley, 2005 (Barkley, , 2006 . Therefore, their driving performance is impaired, which puts themselves as well as the passengers in their vehicles, other drivers, and pedestrians at risk (Cox et al., 2011) . Several studies have reported that adults with ADHD are more likely to experience problems associated with driving, including more fines, accidents, drivingrelated injuries, and the suspension of their driver's license (Barkley et al., 1996 (Barkley et al., , 2002 Barkley and Cox, 2007; Fischer et al., 2007) . One study has reported that drivers with ADHD are twice as likely to be involved in motor vehicle accidents compared with non-ADHD drivers (Ludolph et al., 2009) . A study by Weiss et al. (1979) , which followed the course of ADHD from childhood to adulthood, found that both adolescents and adults with ADHD are more likely to be involved in motor vehicle accidents than adolescents and adults without ADHD. Furthermore, Fischer et al. (2007) found that young adults with ADHD received more fines for reckless driving and driving without a license, were involved in a greater number of minor accidents, had more license suspensions and revocations, made impulsive driving errors more frequently and showed less safe driving habits compared with healthy young adults. Laboratory studies using driving simulators have also reported that individuals with ADHD are more likely to experience collisions during monotonous driving segments compared with non-ADHD controls . These collisions appear to be fatigue-related and occur more frequently during the early morning and late evening . Recently, two studies, one using a driving simulator (Narad et al., 2013) , the other using cars equipped with cameras to measure driving errors (Merkel et al., 2013) , showed that unmedicated adolescents and young adults with ADHD have more variability in lane position and speed, more collisions and more abrupt G-force events (e.g., braking abruptly) in comparison to non-ADHD controls. Distraction factors, such as texting in cell phones while driving, impairs even more the driving performance in the ADHD population (Narad et al., 2013) . Risky behaviors (including Health, Driving and Financial behaviors) in College students with ADHD were related to their symptomatology, but Effortful Control (consisting of activation control, attentional control, and inhibitory control) and Sensation Seeking were mediators between symptoms and behaviors, one counterbalancing the other and influencing differently the different risk behaviors (Graziano et al., 2014) . For these authors, the risky behaviors of individuals with ADHD are not related to their symptoms themselves, but to the ability of the individuals to deal with their impulsivity in situations with more, or less, immediate gratification, depending on their Sensation Seeking tendencies and Effortful Control abilities (Graziano et al., 2014) .
In a recent meta-analysis, Vaa (2014) estimated the relative risk (RR) of accidents for drivers with ADHD. The overall RR for ADHD drivers was 1.36 but decreased to 1.23 when controlling for mileage exposure, as ADHD drivers drive more than controls without ADHD. The major contributor for the RR = 1.23 was the violations of speed. The RR was not significant when property-damage-only accidents were measured (RR =1.07) but was 1.80 (po0.05) when personal injury is considered. An important confounder is the presence of comorbidities, namely oppositedefiant, personality and conduct disorders: RRs were 1.86 (po0.05) for drivers with these comorbidities and 1.31 (not significant) when no comorbidities were present in the ADHD sample. The author also calls attention that the studies did not separate deliberate violations and unintentional driving errors as the former are linked to accidents, the latter are not.
Psychostimulants are the most common medications that are prescribed for the treatment of ADHD (Seixas et al., 2012) , and improve symptoms in 60-90% of individuals (MTA Cooperative Group, 1999; Rappley, 2005; Barry et al., 2009; Wigal, 2009) . Recently, a meta-analysis showed that these drugs are highly efficacious in the treatment of adult ADHD with large effect sizes (Faraone and Glatt, 2010) . Recent guidelines have recommended stimulants as the first treatment choice for ADHD, with non-stimulants recommended as a second treatment choice for individuals with comorbidities such as substance abuse, anxiety, or depression (Pliszka, 2007; Kooij et al., 2010) .
In previous reviews of studies on ADHD and driving performance, Barkley and Cox (2007) and Jerome et al. (2006) concluded that stimulants may improve the driving performance of teenagers and adults, and consequently reduce the risk of citations, license revocations, collisions, accident-related property damage, and mortality. At that time, there were only 7 randomized controlled trials that investigated the effect of medication on driving performance of teens and adults with ADHD. Cox et al. (2011) discussed the findings of these two old reviews and suggested that pharmacological and nonpharmacological approaches may improve driving performance by alleviating ADHD symptoms, which reduces risks to the patients as well as their passengers, other drivers, and pedestrians.
The aim of this study was to conduct a systematic review of the influence of stimulant and non-stimulant drug treatment on driving performance in individuals with ADHD.
Experimental procedures
Our systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) statement (www.prisma-statement.org/state ment.htm). An exhaustive search through March 2013 was per formed using the following databases: PubMed, Lilacs, PsycINFO, EMBASE, Cochrane, Scielo, and www.clinicaltrials.gov. Initial search terms that were used without language restrictions were ADHD, ADD, driving, car, drive, driver, medication, simulator, attention deficit hyperactivity disorder, and attention deficit disorder. A second search was performed that included the terms stimulants, psychostimulants, randomized controlled trials, clinical trials, methylphenidate, amphetamines, lisdexamfetamine, atomoxetine, bupropion, and antidepressants.
Studies were included in our review if they were randomized controlled trials (RCTs) that evaluated the influence of stimulant or non-stimulant drugs on driving performance in individuals with ADHD. Studies were excluded if they were case reports, reviews, observational trials, case series, studies without drug treatments, studies that did not use a simulator or a car to evaluate driving performance, or studies on the influence of alcohol or other illicit drugs on driving performance. Studies that met our inclusion and exclusion criteria were read in full by both authors. Reference lists were also checked to identify other relevant studies. From the studies included in our review, relevant information was independently extracted by both authors, and a structured evidence table was organized to synthesize the data. Effect sizes (Cohen's d, unless otherwise stated) were calculated from the data provided or reproduced if already determined in the papers.
Results
We initially found 345 studies using the PubMed, Cochrane, and EMBASE databases. However, 317 studies were excluded because, after reading the titles and abstracts, they were found to be duplicates or were not related to the subject of this review. The articles for the remaining 28 studies were read in full, and 14 met our inclusion and exclusion criteria. One additional study that met our inclusion and exclusion criteria was found after checking the reference lists of the 14 original studies. Therefore, a total of 15 studies were included in our review (Figure 1) .
The 15 RCTs (see Table 1 for details) included in this analysis were Cox et al. (2000 Cox et al. ( , 2004a Cox et al. ( , 2004b Cox et al. ( , 2006 Cox et al. ( , 2008 Cox et al. ( , 2012 ; Barkley et al. (2005 , Bjørkli et al. (2005) , Verster et al. (2008) , Kay et al. (2009 ), Mikami et al. (2009 ), Biederman et al. (2012a ,2012b and Sobanski et al. (2013) . Although three studies used the same sample, these studies provided new data on driving performance: Mikami et al. (2009) and Cox et al. (2008) used the same sample as Cox et al. (2006) and Biederman et al. (2012b) used the same sample as Biederman et al. (2012a) . All studies were published in English in the year 2000 or later. Effect sizes of the main results are included also included in Table 1 .
These RCTs included a total of 338 subjects, including 283 ADHD patients, 34 healthy controls, and 21 controls with ADHD. All ADHD patients were diagnosed according to the DSM-IV criteria; two studies used the DSM-IV-TR criteria.
Twelve RCTs used a crossover design and three RCTs used a parallel design. Eleven studies were double-blind, three studies were single-blind, and one study was an openlabel study.
The driving simulation varied among the trials. The simulation was measured in either distance or time. For some studies, the driving simulation was conducted at baseline and after a variable time of treatment. Other studies were repeated up to 4 times across the day and night. Different measures of driving performance, such as the number of collisions, average speed, variation in steering, brake reaction time, weaving, and sudden decelerations, were quantified to compare baseline and intervention conditions; frequently a 'composite' or 'overall' driving score was used as primary outcome. When the trial was performed with a car either a rater (sitting in the car during the task) used a checklist to obtain the driving parameters or these were obtained from cameras installed in the car. Although driving outcomes were the same within studies, there was a large variation in the driving parameters that were measured between studies, which made comparisons across studies difficult. Eight studies evaluated the stimulant methylphenidate (MPH) with different release methods: MPH immediate-release (MPH-IR), MPH osmoticcontrolled release oral delivery system (MPH-OROS), and the MPH transdermal system (MTS). Four studies evaluated extended-release mixed amphetamine salts (MAS-XR), three studies evaluated the non-stimulant atomoxetine (ATX), and two studies evaluated the stimulant lisdexamfetamine (LDX). In three studies, the driving evaluation was conducted approximately 60-90 min after the ingestion of a single dose of the drug (Cox et al., 2000; Bjørkli et al., 2005; and Verster et al., 2008) ; in all other studies, tests were conducted a variable number of weeks after starting the medication. In the studies that used ATX, the driving simulation was conducted 3-12 weeks after the medication was started. Twelve studies used a placebo-controlled study design. Four of these studies compared MPH-IR with a placebo (Cox et al., 2000; Bjørkli et al., 2005; Barkley et al., 2005; Verster et al., 2008) , three studies compared MPH-OROS or MAS-XR with a placebo (Cox et al., 2006 (Cox et al., ,, 2008 Mikami et al., 2009) , two studies compared ATX with a placebo Kay et al., 2009) , one study compared MAS-XR with a placebo (Kay et al., 2009) , and two studies compared LDX with a placebo (Biederman et al., 2012a; Biederman et al., 2012b) . One trial compared MPH-OROS with MPH-IR (Cox et al., 2004b) , two studies compared the drug (MPH-OROS or MTS) to a no-drug condition (Cox et al., 2004a; Cox et al., 2012, respectively) , and one study compared ATX to a waiting-list control group (Sobanski et al., 2013) .
The sample size included fewer than 20 patients in seven studies (Cox et al., 2000 (Cox et al., , 2004a (Cox et al., , 2004b Verster et al., 2008; Kay et al., 2009; Cox et al., 2012) . The other five studies included 35, 45, 54, 61, and 43 patients (Bjørkli et al., 2005; Barkley et al., 2005; Cox et al., 2006; Biederman et al., 2012a; Sobanski et al., 2013, respectively) . Two studies (Cox et al., 2008; Mikami et al., 2009 ) used the same sample as Cox et al. (2006) and one study (Biederman et al., 2012b ) used the same sample as Biederman et al. (2012a) .
The MPH dosage depended on the delivery method: from 10 to 120 mg/day for MPH-IR, 18 to 144 mg/day for MPH-OROS, and 10 to 30 mg/day for MTS. The MAS-XR dosage ranged from 15 to 50 mg/day. The ATX dosage varied by study: 1.2 mg/kg/day in one study, a mean dosage of 71.6 mg/day in another study, and a dose titration schedule up to 80 mg/day in a third study. The dosage of LDX ranged from 30 to 70 mg/day.
Eight studies included both male and female patients, and four studies included only male patients. In the two studies that used the same sample as Cox et al. (2006) , one study included both the male and female patients (Mikami et al., 2009 ) and the other included only the male patients (Cox et al., 2008) .
Three studies (Cox et al., 2004a , 2004b and Cox et al., 2006 evaluated teenagers (mean age: 17.2-17.8 years old), and nine studies evaluated adults (mean age: 20.8-38.3 years old). In the two studies (Cox et al., 2000 and Bjørkli et al., 2005 ) that included healthy subjects as controls, the mean age ranged from 21.8 to 31.0 years old. In one study (Sobanski et al., 2013 ) that included ADHD patients who were on a waiting list for treatment as controls, the mean age was 37.479.5 years old.
Ten studies used a driving simulator (Cox et al., 2000 (Cox et al., , 2004b (Cox et al., , 2006 Barkley et al., 2005; Bjørkli et al., 2005; Kay et al., 2009; Mikami et al., 2009; Biederman et al., 2012a; Biederman et al., 2012b) , and four studies were conducted exclusively in cars in different typical driving situations (Cox et al., 2004a (Cox et al., , 2012 Verster et al., 2008; Sobanski et al., 2013) . In one study (Cox et al., 2008) , the evaluations were initially conducted using a simulator followed by two additional evaluations in a car and a simulator, respectively. Five different brands simulators were used. Cox, Barkley and Biederman used the same simulator with the same or slightly different scenarios in more than one study (Cox et al., 2000 (Cox et al., , 2004b (Cox et al., , 2006 (Cox et al., , 2008 Barkley et al., 2005 Biederman et al.2012a Biederman et al. ,2012b . Bjørkli et al. (2005) used a simulator in a single study and Kay et al. (2009) tested two drugs independently (MAS-XR and ATX), but the results are presented in a single paper.
Courses and scenarios varied widely. Usually in a simulation different kinds of scenarios, including highway, country and city driving were included in the same task. Even though these scenarios may reproduce "boring" or "more stimulating" conditions (like a monotonous road or a urban course with different interferences of other cars or pedestrians) they usually are not analyzed separately. In most of the studies the outcomes (driving errors, collisions and so on) are measured considering the whole simulation. One exception is the trial by Bjørkli et al. (2005) where he used 5 different scenarios and analyze the results for each scenario separately. The studies with cars used also different courses, from a 16-mile course with rural, highway and urban driving (Cox et al., 2004a (Cox et al., , 2008 ) to a 100-km highway during normal traffic (Verster et al., 2008) or a 45-min urban course in weekdays during rush hour (Sobanski et al., 2013) . Cox et al. (2012) monitored drivers with cameras on the rearview mirror for 3 months, but do not provide information about the distance driven during these 3 months, where patients drove (urban areas, roads?) and if the different patients drove in different situations.
Overall, most studies indicated that the use of psychostimulant drugs significantly improved driving performance in patients with ADHD. Two studies (Cox et al., 2000; Verster et al., 2008) reported that patients who were treated with MPH-IR had significantly better driving performance than patients (Verster et al., 2008) or non-ADHD controls (Cox et al., 2006 ) that were treated with placebo. Barkley et al. (2005) found that 20 mg of MPH-IR more effectively improved driving performance compared with10 mg; however the 10 mg dose of MPH-IR was more effective than placebo only on number of turn signals, not in other measures.
In one study that included a sample of 35 patients (19 males and 16 females), MPH-OROS significantly improved driving performance measured at 5:00 PM, 8:00 PM, and 11:00 PM compared with placebo or MAS-XR; however, driving performance in patients treated with MAS-XR was not significantly different from patients treated with placebo (Cox et al., 2006) . A subsample of these patients (19 males) was tested again on the road at midnight using a car and on a driving simulator at 1:00 AM. Patients who were treated with MAS-XR but not MPH-OROS showed a significant decline in their driving performance compared with placebo. The authors suggested that MAS-XR may possibly have a rebound effect, although the sample size was not large enough to reach a definite conclusion (Cox et al., 2008) . No gender differences were observed in a post-hoc analysis that compared the driving performance of males (n= 19) and females (n= 16) at 5:00 PM, 8:00 PM and 11:00 PM (Mikami et al., 2009) .
Four studies reported no effects of either MPH-IR (Bjørkli et al., 2005; Verster et al., 2008) or ATX Kay et al., 2009 ) on driving performance compared with a placebo. However, Sobanski et al. (2013) found that driving performance in the ATX group was significantly better than the control group.
Two studies (Cox et al., 2004a (Cox et al., , 2012 ) compared a drug and no-drug condition instead of using a placebo arm, and one study used patients on a treatment waiting list as controls (Sobanski et al., 2013) . Patients treated with MPH-OROS, MTS, or ATX showed better driving performance than patients in the no-drug or waiting-list arms.
From the studies conducted with simulators, six showed efficacy of the drug tested (Cox et al., 2000 , 2004b , 2006 Kay et al., 2009 for MAS-XR and Biederman et al., 2012a ) and 3 trials were negative (Bjorkli et al., 2005; Kay et al., 2009 for ATX) . The studies derived from the study of Cox et al., 2006 (Cox et al., 2008 and Mikami et al., 2009 and from the study of Biederman et al., 2012a (Biederman et al., 2012b were also positive. The five studies conducted with cars showed statistically significant results, three with MPH-OROS (Cox et al., 2004b (Cox et al., , 2008 , one with MPH-IR (Verster et al., 2008) , one with MTS (Cox et al., 2012) and one with ATX (Sobanski et al., 2013) . Nevertheless, in the study of Cox et al. (2008) MPH-OROS, but not MAS-XR, improved driving performance of ADHD patients and in the study of Verster et al. (2008) the statistically significant difference in the standard deviation of lateral position (SDLP) weaving between placebo and MPH-IR was 2.3 cm in a car driving at 95 km/h, that could be considered clinically irrelevant and the SDLP (mean: 21.1 cm with placebo) can be considered within normal range (Verster and Roth, 2011) .
Six studies were completely funded by a pharmaceutical company (Cox et al., 2004a (Cox et al., , 2006 (Cox et al., , 2004b (Cox et al., , 2012 Kay et al., 2009; Biederman et al., 2012a) , one study was partially funded by a pharmaceutical company , and one study was an investigator-initiated sponsored trial (Sobanski et al., 2013) . With one exception , all of these industry-sponsored studies reported a positive result for the drug that the sponsoring company produced. Of the four studies that were funded by universities or foundations, three studies reported positive results of the drug (Cox et al., 2000; Barkley et al., 2005; and Verster et al., 2008) and one study reported negative results of the drug (Bjørkli et al., 2005) .
Although patients in the drug conditions experienced some abdominal pain, nausea, urinary difficulty, decreased appetite, tension, jitteriness, anorexia, weight loss, dry mouth, insomnia, and bruxism, all side effects were reported as mild and not significant Cox et al., 2006; Kay et al., 2009; Biederman et al., 2012a) . However, only one study systematically collected data on the adverse effects of the drug (Biederman et al., 2012a) .
Discussion
Both stimulant and non-stimulant drugs are efficacious in the treatment of ADHD; stimulant drugs produce the largest effect sizes and are therefore the primary treatment choice for ADHD (Seixas et al., 2012) . However, RCTs that have evaluated the effect of ADHD drug treatment on driving performance are relatively scarce. The present review found that across existing RCTs with ADHD patients, stimulant drugs were found to improve driving performance compared with placebo or no-drug conditions, which corroborates and widens the results of previous reviews (Barkley and Cox, 2007; Jerome et al., 2006) . Since these two reviews, 8 trials on the efficacy of drug treatment on driving performance in ADHD were published, adding new information on this subject, testing new drugs (e.g., LDX) and extending and strengthening the findings already published.
The studies that were included in the present review showed that patients who were treated with MPH-OROS had better driving performance than patients in the MAS-XR, placebo, or no-drug conditions (Cox et al., 2004a and Cox et al., 2006) . MPH-OROS and MPH-IR similarly improved driving performance during the day. However, MPH-IR lost its efficacy during the evening, which may increase the risk of driving problems for patients with ADHD (Cox et al., 2004b) . In one study that used the same sample as Cox et al. (2006) no gender differences in MPH-OROS efficacy were found (Mikami et al., 2009 ). In another study that used the same sample as Cox et al. (2006) , MPH-OROS maintained its efficacy late at night. However, a rebound effect of MAS-XR was observed, which may enhance the risk of driving problems for ADHD patients who are taking this medication (Cox et al., 2008) .
Of the five studies that evaluated MPH-IR, three studies reported improvements in performance compared with placebo or showed similar results compared with MPH-OROS, even for relatively low doses Cox et al., 2000 Cox et al., , 2004b . These studies used a driving simulator. Two of these studies tested relatively inexperienced drivers (Cox et al., 2000 (Cox et al., , 2004b and one study tested adult drivers with more years of experience . Among experienced adult drivers, no clear difference was observed between the 10 and 20 mg doses of MPH-IR, perhaps because the more experienced drivers were less likely to make errors. Two studies that used MPH-IR, however, did not report clear differences between the MPH-IR and placebo conditions. The first study (Bjørkli et al., 2005) tested experienced drivers in tasks that were not as complex as real-world driving situations, which may explain the negative finding. Although the authors of the second study (Verster et al., 2008) found a 2.3 cm difference in weaving on a road between the drug and placebo conditions, this difference may be considered negligible in a car that is traveling at 95 km/h. Finally, as previously described, tests that were conducted late in the evening revealed that patients in the MPH-IR group showed poorer driving performance compared with patients in the MPH-OROS group (Cox et al., 2004b) . Therefore, the improvement in driving performance observed with MPH-IR seems to depend on the conditions under which the study was performed and the results may not be as consistent as the results with MPH-OROS. The short duration of action of MPH-IR may also be related to these results.
One study reported that long-acting MTS treatment led to a reduction in the number of collisions when patients drove their own cars (Cox et al., 2012) . The results of this study, however, may have been compromised due to the small sample size and the large variability in the percentage of days that patients administered MTS correctly. Furthermore, this study was an open-label study in which patients receiving treatment were compared with a no-drug condition rather than a placebo condition.
In addition to the previously described studies on MAS-XR (Cox et al., 2006 (Cox et al., , 2008 Mikami et al., 2009) , Kay et al. (2009) concluded that MAS-XR treatment had better effects on driving performance than a placebo in a small sample of ADHD patients. Their results agreed with the results reported by Cox et al. (2006) . However, Kay et al. (2009) did not test driving performance late in the evening, and therefore this study was not able to observe a possible rebound effect.
Two studies on ATX produced negative findings Kay et al., 2009) , perhaps because both studies evaluated more experienced adult drivers. In the Kay et al. (2009) study, the highest dose of ATX that was given was 80 mg/day, which may not be high enough for some patients. , however, used a 1.2 mg/ kg/day dose and also observed negative results. Both studies had small sample sizes and used crossover designs with no washout between phases. Another study (Sobanski et al., 2013) showed improvements in driving performance in patients that used ATX compared with a waiting-list control group. This study found that the ATX group had a significantly reduced number of driving errors in three of four scores (attention, risk-related self-control, and driver skills) on the Standardized Driving Behavior Observation (SDBO) compared with the waiting-list control group. However, an important limitation of this study is that the study was single-blind: patients but not traffic psychologists were aware of the condition (medication or waiting list) during the driving test. The authors did not address the influence of these conditions on the results of the study. Furthermore, in both studies that reported negative results Kay et al., 2009) , the driving tests were conducted 3-4 weeks after taking the medication. This time frame may have contributed to the negative results because ATX may take up to 12 weeks to achieve its full efficacy. The study by Sobanski et al. (2013) , which had a bigger sample size and tested the patients after 12 weeks of exposure to ATX, reported positive results.
The two studies on the efficacy of LDX, which reported results from the same sample, concluded that LDX has a positive effect on driving performance compared with placebo (Biederman et al., 2012a (Biederman et al., , 2012b . Although the sample size was relatively large, no information was given about the different ADHD subtypes or gender differences within the sample. The difference between the drug and placebo conditions may have been enhanced because the drivers were young and relatively inexperienced and because the second session of the simulator presented a difficult driving scenario with five surprise events.
It is noteworthy that in all trials, with the exception of Cox et al. (2008) study with MAS-XR where a rebound effect was observed with worsening of driving performance, treatment with psychostimulants or ATX in therapeutic dosages did not had a negative impact on driving performance of ADHD patients.
Both studies conducted in simulators and in cars show differences between experimental and control conditions in ADHD patients. So, negative results observed in some studies seem not to be due to a kind of videogame-like stimulating effect produced by simulators. Studies using cars are obviously more realistic, but at the same time, measurements are more difficult to obtain as cameras or an evaluator sitting in the car may inhibit the driver and make him conduct more cautiously. The evaluation of the efficacy of the drug does not seem to be influenced only by the fact that the study is performed on cars or simulators. Other variables, such as the kind of courses and scenarios may also have a more important impact on the results of the trials.
Although the results of our review suggest that stimulants improve driving performance in ADHD, some methodological limitations of the RCTs should be considered. The relatively small number of RCTs prevents us from drawing clear conclusions. Although we reviewed 15 studies, three of these studies used the same sample to examine additional influences of drug treatments on driving performance. Therefore, only 12 original studies are included in this review. Furthermore, most studies employed small sample sizes (i.e., less than 20 subjects); only five studies employed sample sizes larger than 30 subjects. So, effect sizes should be interpreted with caution as they could be biased due to the small sample size of most of the trials (Elbourne et al., 2002; Durlak 2009 ). Furthermore, most studies included only male patients or a disproportionally small number of female patients. Two exceptions are the studies by Mikami et al. (2009) , which specifically examined gender differences, and Biederman et al. (2012a Biederman et al. ( , 2012b ), which did not investigate possible gender differences. Although previous studies have reported that males and females exhibit different driving styles (Vavrik, 1997; Bina et al., 2006; Elliott et al., 2006; Classen et al., 2013) , it is not currently known whether males and females with ADHD drive differently. Therefore, it is difficult to extrapolate findings from studies that primarily used male patients to the female population.
The age and driving experience of the patients may also influence the results. Healthy adolescents and young adults drive more dangerously than older adults (Bina et al., 2006; Elliott et al., 2006) . We observed that RCTs that included teenagers and young adults with ADHD tended to yield positive results, whereas studies that included older adults with ADHD tended to yield negative results. This observation suggests that less-skilled drivers may derive greater benefits from psychostimulants than more-skilled drivers. Furthermore, experienced adult drivers with ADHD may be more aware of their symptoms and limitations and therefore may drive more carefully even without medications. Some studies enforced inclusion criteria such as a minimum number of years of driving experience or a minimum number of kilometers driven per year, and therefore did not evaluate the potential relationship between years of experience and driving performance. In addition, some studies excluded patients whose driver's license had been revoked, which may have prevented the inclusion of a potentially more severe ADHD population (Kay et al., 2009; Biederman et al., 2012a) .
ADHD subtypes and the presence of comorbidities were not considered in most studies. In some studies, patients with the most severe comorbidities were excluded, whereas other studies included patients with comorbidities such as conduct disorder, obsessive-compulsive disorder, and substance abuse. Furthermore, some studies selected patients with either combined or inattentive ADHD subtypes. Studies seldom included hyperactive-impulsive subjects. Therefore, the influence of drug treatment on the performance of these "more dangerous" drivers could not be evaluated. This subtype would be, at least theoretically, more prone to make deliberate violations than unintentional errors hence increasing the risk of mishaps with more severe consequences (Vaa, 2014) .
Three studies used a parallel design (Biederman et al., 2012a (Biederman et al., , 2012b Sobanski et al., 2013) and the remaining studies employed a balanced crossover design. However, some of these crossover studies did not include a washout period between the two phases of the trial. Although the drugs that were used in these studies have a maximum halflife of 12-14 h, a possible carryover effect cannot be excluded. In addition, although most studies were doubleblind, patients who have previously taken stimulants may have been able to distinguish between the drug and placebo conditions. Allocation concealment was also not employed in any of the studies. Furthermore, trials were conducted relative to drug administration in two different ways. A driving test was given either approximately 1.5 h after a single drug treatment or some weeks after a long-term drug treatment. It is not clear how these two types of study designs may have influenced the results. Studies that examine the acute effect of a single treatment are not as representative of a real-world situation as studies that evaluate patients at both baseline and after several weeks of drug treatment, which can examine the long-term use of the drug.
In the studies included in the present review, driving performance was evaluated in either cars or driving simulators. Even sophisticated simulator software and hardware, however, cannot fully mimic the complex act of driving. Participants who interacted with driving simulators may have been aware that no real risk to themselves or others existed, and therefore these participants may have driven with less engagement. Furthermore, two studies Biederman et al., 2012a ) that used driving simulators had to exclude participants who experienced simulator sickness, which is an adverse event in which drivers experienced nausea and vertigo in the driving simulator (Brooks et al., 2010; Classen et al., 2011) .
Participants who are required to drive their own cars, equipped with either cameras or a human observer, may drive more carefully. Studies in which participants use their own cars may also allow for lengthier trials (e.g., using cameras to detect errors or risky situations) that reflect more realistic driving conditions. However, in some studies (Cox et al., 2004a; Sobanski et al., 2013) , the presence of an observer in the rear seat may promote more careful driving, which would reduce the ability to detect differences between control and experimental conditions. Furthermore, although observers had a standard checklist of errors to record during the driving tests, a potential subjective bias may influence their scores.
Among the studies that employed a driving simulator, there was a wide variation in the types of simulators and simulation software. Studies utilized urban driving scenarios, rural driving scenarios, or a combination of urban and rural situations. The duration of the simulations varied from 12 to 75 min. Shorter durations may not be sufficient to detect differences between the drug and placebo conditions because drivers had not yet grown weary of the task. Studies that have used continuous performance tasks have shown that inattention-and impulsivity-related errors occur after a long time on task when subjects eventually lose their concentration or react impulsively to a stimulus (HuangPollock et al., 2012; Reimer et al., 2007) . Because practice effects may also influence results, in some studies the driving scenarios were changed from trial to trial. These different scenarios should have the same difficulty level, however, to avoid the introduction of a confounding effect between the experimental and control conditions.
None of the reviewed studies considered the role of motor coordination in driving performance. Developmental coordination disorder has been described in children with ADHD and has been shown to persist into young adulthood (Rasmussen and Gillberg, 2000) . These individuals are typically unskilled, clumsy, and have difficulty with handwriting. Because driving demands good motor coordination (Sobanski et al., 2008) , ADHD drivers with poor motor coordination may exhibit worse driving performance than ADHD drivers with unaffected motor coordination.
The financing of drug trials by the pharmaceutical companies may influence the results by favoring the drug of the manufacturer. In our review, nine of eleven trials that were partially or completely financed by a pharmaceutical company yielded a positive result for the drug. Even though this observation alone does not indicate that the trials were compromised, this fact should be considered in the interpretation of the results. It has to be considered that three of the four trials that were financed by universities or foundations also reported positive results.
Financial compensation was provided to the participants in some of the studies, and varied from US$20.00 to US$600.00. No study, however, estimated the influence of this incentive on the motivation of subjects to demonstrate good driving performance (Festinger et al., 2008; Largent et al., 2012) .
The methodological limitations of the trials are important factors to be considered when analyzing the results. They suggest that an 'ideal' trial to test the efficacy of drugs on the driving performance of ADHD patients is yet to be done. On the other hand, despite this, the fact that most of the trials show a positive result may speak in favor of the consistence of the results observed.
RCTs with ADHD patients show that MPH-OROS improves driving performance compared with MAS-XR, placebo, or nodrug conditions. Although MPH-OROS and MPH-IR produce similar improvements in driving performance during the day, MPH-IR loses its efficacy in the evening. MAS-XR also improves driving performance, but loses its efficacy and leads to worse driving performance in the evening. MTS may have a positive effect on driving, but drug compliance varied widely across patients. LDX may also have a positive effect on driving, but so far only two studies with the same sample are published. Studies of the effect of ATX on driving performance report conflicting results. Across all studies, the effect of the drug on improvement in driving performance was more relevant among teenagers and young adults.
Adolescents and young adults with ADHD, usually less experienced drivers are, at the same time, putting themselves in risk of negative driving outcomes (e.g., by using cell phones and texting or by increased risk taking and behaviors secondary to hyperactivity/impulsivity and distraction) (Graziano et al., 2014; Merkel et al., 2013; Narad et al., 2013) , specially if they have comorbidities such as Oppositional Defiant Disorder or Conduct Disorders (Vaa, 2014) . The investigation of the driving style should be part of the thorough psychiatric examination of this population as the reduction of risky driving is an important priority of public health. The evidence so far shows that a proper pharmacological intervention improve ADHD symptoms and may reduce risky driving behaviors and their negative consequences.
